Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.20
SPNC's Cash to Debt is ranked lower than
90% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. SPNC: 0.20 )
Ranked among companies with meaningful Cash to Debt only.
SPNC' s 10-Year Cash to Debt Range
Min: 0.19  Med: 10000.00 Max: No Debt
Current: 0.2
Equity to Asset 0.30
SPNC's Equity to Asset is ranked lower than
88% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. SPNC: 0.30 )
Ranked among companies with meaningful Equity to Asset only.
SPNC' s 10-Year Equity to Asset Range
Min: 0.3  Med: 0.74 Max: 0.89
Current: 0.3
0.3
0.89
F-Score: 2
Z-Score: 1.12
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -23.29
SPNC's Operating margin (%) is ranked lower than
68% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. SPNC: -23.29 )
Ranked among companies with meaningful Operating margin (%) only.
SPNC' s 10-Year Operating margin (%) Range
Min: -34.35  Med: -6.01 Max: 4.35
Current: -23.29
-34.35
4.35
Net-margin (%) -26.24
SPNC's Net-margin (%) is ranked lower than
69% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. SPNC: -26.24 )
Ranked among companies with meaningful Net-margin (%) only.
SPNC' s 10-Year Net-margin (%) Range
Min: -32.33  Med: -3.04 Max: 23.17
Current: -26.24
-32.33
23.17
ROE (%) -39.79
SPNC's ROE (%) is ranked lower than
73% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. SPNC: -39.79 )
Ranked among companies with meaningful ROE (%) only.
SPNC' s 10-Year ROE (%) Range
Min: -44.49  Med: -2.74 Max: 29.8
Current: -39.79
-44.49
29.8
ROA (%) -13.71
SPNC's ROA (%) is ranked lower than
61% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. SPNC: -13.71 )
Ranked among companies with meaningful ROA (%) only.
SPNC' s 10-Year ROA (%) Range
Min: -28.33  Med: -2.22 Max: 18.65
Current: -13.71
-28.33
18.65
ROC (Joel Greenblatt) (%) -79.00
SPNC's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. SPNC: -79.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPNC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -90.13  Med: -16.89 Max: 34.27
Current: -79
-90.13
34.27
Revenue Growth (3Y)(%) 10.00
SPNC's Revenue Growth (3Y)(%) is ranked higher than
74% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. SPNC: 10.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SPNC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.7  Med: 5.70 Max: 29.4
Current: 10
-3.7
29.4
» SPNC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SPNC Guru Trades in Q3 2014

Ron Baron 309,727 sh (+412.11%)
» More
Q4 2014

SPNC Guru Trades in Q4 2014

Steven Cohen 70,900 sh (New)
Ron Baron 270,280 sh (-12.74%)
» More
Q1 2015

SPNC Guru Trades in Q1 2015

Steven Cohen 559,000 sh (+688.43%)
Ron Baron 862,579 sh (+219.14%)
» More
Q2 2015

SPNC Guru Trades in Q2 2015

Ron Baron 2,340,509 sh (+171.34%)
Steven Cohen 187,300 sh (-66.49%)
» More
» Details

Insider Trades

Latest Guru Trades with SPNC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on The Spectranetics Corp

Baron Funds Comments on The Spectranetics Corp. - Aug 19, 2015

The Spectranetics Corporation (NASDAQ:SPNC) is a medical device company that specializes in equipment that clears plaque from cardiac and peripheral (arm and leg) arteries. Shares fell after the company reported that it had missed revenues in the first quarter and lowered full year guidance. We believe the market misunderstood certain dynamics and bought more near the bottom. (Randy Gwirtzman)





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Spectranetics Corporation - Feb 26, 2014

The Spectranetics Corporation (NASDAQ:SPNC) is a manufacturer of medical devices that assist in the treatment of peripheral arterial disease and also with the removal of coronary leads used for implanted devices such as pacemakers and defibrillators. Shares were up 46% in the quarter. Most of the company's devices use disposable products that lead to a highly recurring revenue stream. The company is on the verge of opening up large new markets with the expected 2014 approval of a new laser based device that can open up arteries that have previously been stented. If approved, it will be the only device on the market that has this capability.



From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 letter to shareholders.

Check out Ron Baron latest stock trades

Top Ranked Articles about The Spectranetics Corp

Baron Funds Comments on The Spectranetics Corp.
The Spectranetics Corporation (NASDAQ:SPNC) is a medical device company that specializes in equipment that clears plaque from cardiac and peripheral (arm and leg) arteries. Shares fell after the company reported that it had missed revenues in the first quarter and lowered full year guidance. We believe the market misunderstood certain dynamics and bought more near the bottom. (Randy Gwirtzman) Read more...

Ratios

vs
industry
vs
history
Forward P/E 357.14
SPNC's Forward P/E is ranked lower than
97% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.31 vs. SPNC: 357.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.10
SPNC's P/B is ranked lower than
75% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. SPNC: 5.10 )
Ranked among companies with meaningful P/B only.
SPNC' s 10-Year P/B Range
Min: 0.78  Med: 4.44 Max: 13.1
Current: 5.1
0.78
13.1
P/S 2.86
SPNC's P/S is ranked higher than
50% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. SPNC: 2.86 )
Ranked among companies with meaningful P/S only.
SPNC' s 10-Year P/S Range
Min: 0.69  Med: 4.09 Max: 8.47
Current: 2.86
0.69
8.47
Current Ratio 1.95
SPNC's Current Ratio is ranked lower than
63% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. SPNC: 1.95 )
Ranked among companies with meaningful Current Ratio only.
SPNC' s 10-Year Current Ratio Range
Min: 1.4  Med: 2.76 Max: 8.52
Current: 1.95
1.4
8.52
Quick Ratio 1.52
SPNC's Quick Ratio is ranked lower than
60% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. SPNC: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
SPNC' s 10-Year Quick Ratio Range
Min: 1.2  Med: 2.38 Max: 7.99
Current: 1.52
1.2
7.99
Days Inventory 153.09
SPNC's Days Inventory is ranked lower than
60% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. SPNC: 153.09 )
Ranked among companies with meaningful Days Inventory only.
SPNC' s 10-Year Days Inventory Range
Min: 76.33  Med: 88.57 Max: 148.51
Current: 153.09
76.33
148.51
Days Sales Outstanding 60.55
SPNC's Days Sales Outstanding is ranked higher than
63% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. SPNC: 60.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPNC' s 10-Year Days Sales Outstanding Range
Min: 48.49  Med: 62.76 Max: 111.77
Current: 60.55
48.49
111.77

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 117.36
SPNC's Price/Projected FCF is ranked lower than
100% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. SPNC: 117.36 )
Ranked among companies with meaningful Price/Projected FCF only.
SPNC' s 10-Year Price/Projected FCF Range
Min: 0.19  Med: 13.08 Max: 336.5
Current: 117.36
0.19
336.5
Price/Median PS Value 0.70
SPNC's Price/Median PS Value is ranked higher than
75% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. SPNC: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
SPNC' s 10-Year Price/Median PS Value Range
Min: 0.19  Med: 0.89 Max: 1.88
Current: 0.7
0.19
1.88
Earnings Yield (Greenblatt) (%) -6.20
SPNC's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. SPNC: -6.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPNC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -6.25  Med: 0.70 Max: 31.1
Current: -6.2
-6.25
31.1

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 246 272
EPS($) -1.01 -0.96
EPS without NRI($) -1.01 -0.96

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:SC7.Germany,
The Spectranetics Corp is incorporated under the laws of Delaware and formed in 1984. The Company develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company has two operating segments that are identified on a geographic basis: U.S. Medical and International Medical. U.S. Medical and International Medical offer the same products and services but operate in different geographic regions, have different distribution networks and different regulatory environments. Its products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. Approximately 68% of its disposable product revenue is from products used in connection with its proprietary excimer laser system, the CVX-300. Its single-use laser catheters contain up to 250 small diameters, flexible optical fibers that can access difficult to reach peripheral and coronary anatomy and produce evenly distributed laser energy at the tip of the catheter for more uniform ablation. Its disposable products are develops in two categories: Vascular Intervention (VI) and Lead Management (LM). Vascular Intervention products include; support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions, drug delivery catheters for vascular delivery of drugs and diagnostic agents. Lead Management products include: excimer laser sheaths; non-laser sheaths; and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. Its competitors are manufacturers of products used in competing therapies within the peripheral and coronary atherectomy markets, such as: atherectomy and thrombectomy, using mechanical methods to remove arterial blockages, balloon angioplasty and stents, specialty balloon angioplasty, bypass surgery and amputation. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA. FDA regulations govern.
» More Articles for SPNC

Headlines

Articles On GuruFocus.com
Baron Funds Comments on The Spectranetics Corp. Aug 19 2015 
Baron Funds Comments on Spectranetics Corporation Feb 26 2014 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 08 2010 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 06 2009 
Spectranetics Corp. Reports Operating Results (10-Q) Aug 10 2009 
Spectranetics Corp. Reports Operating Results (10-Q) May 11 2009 
Spectranetics to Hold 2008 Fourth Quarter Financial Results Conference Call on February 19 Feb 12 2009 
Spectranetics Cross-Pilot Product Receives FDA Clearance Dec 15 2008 
Weekly CEO Buys Highlight: Spectranetics Corp., Noven Pharmaceuticals Inc., Dolan Media Company, Mod Sep 09 2008 

More From Other Websites
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of The Spectranetics Corporation of... Sep 02 2015
Robbins Arroyo LLP: The Spectranetics Corporation (SPNC) Misled Shareholders According to a Recently... Sep 01 2015
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against... Aug 31 2015
Spectranetics Corporation Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor... Aug 31 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Aug 28 2015
IMPORTANT SHAREHOLDER DEADLINE: Khang & Khang LLP Announces the Filing of a Securities Class Action... Aug 28 2015
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against The Spectranetics... Aug 28 2015
SPECTRANETICS CORP Files SEC form 8-K, Other Events Aug 28 2015
Deadline Alert: The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action... Aug 28 2015
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against... Aug 28 2015
GPM Files Securities Class Action Lawsuit against The Spectranetics Corporation Aug 27 2015
Spectranetics Names Stacy McMahan Chief Financial Officer Aug 27 2015
SPECTRANETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Aug 27 2015
Spectranetics Names Stacy McMahan Chief Financial Officer Aug 27 2015
Street Talk: AAP, SNDK, NNBR & SPNC Aug 18 2015
Needham: Spectranetics Isn't Just A Buy, It's Now A 'Strong Buy' Aug 18 2015
Spectranetics upgraded by Needham Aug 18 2015
Boston Scientific Corp. Earnings Q2*, 2015 Aug 10 2015
SPECTRANETICS CORP Financials Aug 07 2015
ABIOMED, Inc.: Leads amongst peers with strong fundamentals Aug 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK